Business
RAFARMA ENTER $50,000,000 CEFTRIAXONE MARKET AND SIGNS LONG TERM NATIONAL AND REGIONAL DISTRIBUTION CONTRACTS
RAFARMA ENTER $50,000,000 CEFTRIAXONE MARKET AND SIGNS LONG TERM NATIONAL AND REGIONAL DISTRIBUTION CONTRACTS.
About this update from Rafarma Pharmaceuticals, Inc. (wy)
[{"type":"text","content":"Ceftriaxone Production\n\nRafarma is pleased to announce commencement of\nproduction of the antibiotic Ceftriaxone. Ceftriaxone treats inflammatory\ninfections of the organs of the abdominal cavity, including peritonitis, as\nwell as inflammatory diseases of the gastrointestinal and bile-excreting tracts.\nAccording to 2011 official statistics, the market for Ceftriaxone in Russia is\nestimated at more than $51 million (USD) annually. As a participant in the Russian\nFederal Program for Domestic-Produced Vital Drugs, Rafarma intends to\ntake as much as 50% of the Russian market for Ceftriaxone.\n\nNew National and Regional\nDistribution Contracts\n\nZAO ?SIA International? and the Russian\nnational retail chain OAO ?A5\nPharmacy Ltd.? have entered into\nlong-term distribution contracts giving Rafarma an overnight national presence\nin the Russian Federation retail pharmaceutical market. \n\nCEO David Anderson stated, ?Rafarma's increase\nin production and penetration of market share becomes even more assured with\nthe 17 national distributors we have signed to long term agreements. These contracts were an integral part of Rafarma?s\nexpansion plan and will play a vital role in the expansion of operations. Rafarma has positioned itself to become one\nof the five leading pharmaceutical companies in the Russian Federation.?\n\nMr. Anderson went on to say, ?The\nagreements with these drug store chains and pharmaceutical supply companies\nmoves Rafarma in a very positive\ndirection and also shows the respect these companies have for Rafarma. I am extremely pleased that we get to work with\nsuch qualified partners that have the confidence in Rafarma to lock in long-term\ncontracts.\"\n\nABOUT Ceftriaxone: Ceftriaxone is produced for injections and\nwill be packaged in 10 ml. bottles with single gram dosages. Ceftriaxone shall be produced in Unit 2 of\nRafarma?s Terbuni plant. Unit 2 specializes in the production of cephalosporin-based\nproducts and bottle-packaged injection products.\n\nABOUT Rafarma Pharmaceuticals:\nRafarma Pharmaceuticals is a Russia-based multi-product pharmaceutical company\nproducing generic antibiotics and specialty pharmaceuticals, in addition to its\nown line of proprietary products that are approved by the Ministry of Health of\nthe Russian Federatio...